연구동향 분석

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment

Desmond Y. H. Yap Kevin S. H. Liu Yu-Chun Hsu Grace L. H. Wong Ming-Chang Tsai Chien-Hung Chen Ching-Sheng Hsu Yee Tak Hui Michael K. K. Li Chen-Hua Liu Yee-Man Kan Ming-Lung Yu Man-Fung Yuen 2020년

논문상세정보
인용/피인용
' Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Glecaprevir and pibrentasvir
  • hepatitis c
  • renal insuffi ciency
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
177 0

0.0%

' Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment' 의 참고문헌

  • Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis
    Curry MP [2015]
  • Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection
    Foster GR [2015]
  • Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6infection
    Feld JJ [2015]
  • Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
  • Prescribing for patients on dialysis
    Smyth B [2016]
  • Peritoneal dialysis in Asia
    Kwong VW [2015]
  • New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant
    Fabrizi F [2016]
  • Meta-analysis of observational studies : hepatitis C and survival after renal transplant
    Fabrizi F [2014]
  • Management of hepatitis C virus infection in the Asia-Pacific region : an update
    Lim SG [2017]
  • Letter : telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis
    Wiegand J [2014]
  • KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease
  • In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir
    Ng TI [2017]
  • Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?
    Fabrizi F [2012]
  • High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy : an integrated analysis of HCV genotype 1-6 patients without cirrhosis
    Puoti M [2018]
  • Hepatitis C virus genotype 6 : virology, epidemiology, genetic variation and clinical implication
    Thong VD [2014]
  • Glecaprevir/pibrentasvir in patients with chronic HCV genotype 3 infection : an integrated phase 2/3 analysis
    Flamm S [2019]
  • Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3infection
    Zeuzem S [2018]
  • Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis
    Kwo PY [2017]
  • Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment
    Gane E [2017]
  • Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment
    Poordad F [2017]
  • Evaluation of telaprevircontaining triple therapy in the treatment of chronic hepatitis C in hemodialysed patients
    Kaya S [2015]
  • Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection(ENDURANCE-5, 6) : an open-label, multicentre, phase 3b trial
    Asselah T [2019]
  • Efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in treatment-naive and treatmentexperienced asian adults with chronic hepatitis C virus genotype (GT)1 to GT6 infection with compensated cirrhosis and with or without human immunodeficiency virus co-infection (VOYAGE-2)
  • Detection and clinical features of hepatitis C virus type 6 infections in blood donors from Hong Kong
    Prescott LE [1996]
  • Boceprevir-based triple antiviral therapy for chronic hepatitis C virus infection in kidney-transplant candidates
    Mehawej M [2015]
  • Aspects of immune dysfunction in end-stage renal disease
    Kato S [2008]
  • Antiviral therapy(pegylated interferon and ribavirin)of hepatitis C in dialysis patients : metaanalysis of clinical studies
    Fabrizi F [2014]
  • Anti-viral triple therapy with telaprevir in haemodialysed HCV patients : is it feasible?
    Dumortier J [2013]
  • A study to evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in treatment-naive and treatment-experienced, non-cirrhotic asian adults with chronic hepatitis C virus genotype (GT) 1 to GT6 infection with or without human immunodeficiency virus co-infection (VOYAGE-1)